Immune Design Competitors and Similar CompaniesClear all
Immune Design's competitors and similar companies include Enara Bio and ImmunoGen.
 Immune Design Immune Design is a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. |  Enara Bio Enara Bio (formerly known as Ervaxx) is a biotech company specializing in the use of Dark Antigens to deliver vaccines and other immunotherapies for treating and preventing cancer. |  ImmunoGen ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. | |
Founding Date | Founding Date 2008 | Founding Date 2016 | Founding Date 1981 |
Type | Type Subsidiary | Type Private | Type Public |
Tags | |||
Locations | Locations Seattle, US HQ South San Francisco, US | Locations Oxford, GB HQ London, GB London, GB Oxford, GB | Locations Waltham, US HQ |
Employees | Employees 4813% decrease | Employees 622% increase | Employees 277161% increase |
Financial | |||
Revenue (est.) | Revenue (est.) $2.2m (FY, 2018) | Revenue (est.) N/A | Revenue (est.) $108.8m (FY, 2022) |
Cost of goods | Cost of goods $1.4m (FY, 2018) | Cost of goods N/A | Cost of goods $176k (FY, 2022) |
Gross profit | Gross profit $761k (FY, 2018) | Gross profit N/A | Gross profit $108.6m (FY, 2022) |
Net income | Net income ($54.8m) (FY, 2018) | Net income N/A | Net income ($222.9m) (FY, 2022) |
Funding | |||
Total funding raised | Total funding raised N/A | Total funding raised $ 17.5m | Total funding raised $ 56m |
For sources of this data, please see the company profile
View Company Profiles
Enara Bio
HQ
Oxford, GB
Employees
62↑ 2% increase
Enara Bio (formerly known as Ervaxx) is a biotech company specializing in the use of Dark Antigens to deliver vaccines and other immunotherapies for treating and preventing cancer.
View companyImmunoGen
HQ
Waltham, US
Employees
277
ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.
View company